Treatment of metastatic colorectal cancer is based upon the assumption that metastases are homogeneous within a patient. We quantified immune cell types of 603 whole-slide metastases and primary colorectal tumors from 222 patients. Primary lesions, and synchronous and metachronous metastases, had a heterogeneous immune infiltrate and mutational diversity. Small metastases had frequently a low Immunoscore and T and B cell score, while a high Immunoscore was associated with a lower number of metastases. Anti-epidermal growth factor receptor treatment modified immune gene expression and significantly increased T cell densities in the metastasis core. The predictive accuracy of the Immunoscore from a single biopsy was superior to the one of pro...
Colorectal cancer (CRC) still represents the third most commonly diagnosed type of cancer in men and...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
The comprehensive analysis of patients with a complete resection of all metastases reveals the heter...
Treatment of metastatic colorectal cancer is based upon the assumption that metastases are homogeneo...
Despite the development of novel therapies and advanced surgical techniques, colorectal cancer (CRC)...
Simple Summary Metastasis is the main cause for cancer mortality. The most common metastatic sites o...
Simple Summary Metastasis is the main cause for cancer mortality. The most common metastatic sites o...
This study assesses how the metastatic immune landscape is impacting the response to treatment and t...
Cancer-related immunity has been identified as playing a key role in the outcome of colorectal cance...
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in ...
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in ...
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in ...
Purpose: To evaluate immune cell infiltration, the programmed death-1/programmed death ligand-1 (PD-...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
Colorectal cancer (CRC) still represents the third most commonly diagnosed type of cancer in men and...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
The comprehensive analysis of patients with a complete resection of all metastases reveals the heter...
Treatment of metastatic colorectal cancer is based upon the assumption that metastases are homogeneo...
Despite the development of novel therapies and advanced surgical techniques, colorectal cancer (CRC)...
Simple Summary Metastasis is the main cause for cancer mortality. The most common metastatic sites o...
Simple Summary Metastasis is the main cause for cancer mortality. The most common metastatic sites o...
This study assesses how the metastatic immune landscape is impacting the response to treatment and t...
Cancer-related immunity has been identified as playing a key role in the outcome of colorectal cance...
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in ...
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in ...
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in ...
Purpose: To evaluate immune cell infiltration, the programmed death-1/programmed death ligand-1 (PD-...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
Colorectal cancer (CRC) still represents the third most commonly diagnosed type of cancer in men and...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...